US Broker Ratings

Kura Oncology, Inc. (KURA) Stock Analysis: Exploring a Potential 163% Upside in Biotech

For investors with an eye on the biotechnology sector, Kura Oncology, Inc. (NASDAQ: KURA) presents a compelling opportunity amid the dynamic landscape of cancer therapeutics. With a market capitalization of..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring 100% Upside Potential Amid Biotech Innovations

Relay Therapeutics, Inc. (NASDAQ: RLAY) is capturing the attention of investors with its innovative approach to transforming drug discovery processes within the biotechnology sector. As a clinical-stage precision medicines company,..

AMN Healthcare Services Inc (AMN) Stock Analysis: Navigating Challenges with Strategic Solutions

AMN Healthcare Services Inc (NYSE: AMN) stands as a key player in the U.S. healthcare staffing and solutions sector, providing a wide range of technology-enabled workforce services. Despite facing significant..

Talkspace, Inc. (TALK) Stock Analysis: A 64.95% Potential Upside Beckons Investors

Talkspace, Inc. (TALK) is steadily carving its niche within the healthcare sector, specifically in the health information services industry. This virtual behavioral healthcare company has been making waves by offering..

Akso Health Group (AHG) Investor Outlook: Exploring the 415.80% Revenue Surge Amidst Challenging Metrics

Investors with a keen eye on the healthcare sector, particularly in medical distribution, may find Akso Health Group (NASDAQ: AHG) an intriguing case study. With its roots in social e-commerce..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Uncovering a 35.76% Potential Upside in Biotech Innovation

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a dynamic player in the burgeoning field of gene editing, presents a compelling case for investors with a keen eye on the biotechnology sector. With..

GH Research PLC (GHRS) Investor Outlook: Potential 149% Upside in the Biotech Sector

GH Research PLC (NASDAQ: GHRS), an innovative player in the biotechnology sector, is generating significant buzz among investors with its promising pipeline of treatments for depression and other psychiatric disorders...

Savara Inc. (SVRA) Investor Outlook: Exploring a 186% Upside Potential in the Biotech Sector

Savara Inc. (NASDAQ: SVRA), a Langhorne, Pennsylvania-based biopharmaceutical company, has garnered significant attention in the healthcare sector, particularly within the biotechnology industry. With a focus on rare respiratory diseases, Savara’s..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: A 315% Potential Upside in the Biotechnology Sector

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a pioneering entity in the healthcare sector, specifically within the biotechnology industry, is capturing the attention of investors with its remarkable potential upside of 315.53%...

Embecta Corp. (EMBC) Stock Analysis: Unveiling a 22.64% Potential Upside Amid Promising Revenue Growth

Embecta Corp. (NASDAQ: EMBC), a notable player in the healthcare sector, specializes in medical instruments and supplies, focusing on innovative solutions for diabetes management. With a market capitalization of $794.81..

Definitive Healthcare Corp. (DH) Stock Analysis: Unveiling a 47.32% Potential Upside

Definitive Healthcare Corp. (NASDAQ: DH) presents a compelling opportunity for investors seeking exposure to the healthcare sector’s information services niche. With a market capitalization of $320.59 million, this Massachusetts-based company..

Xencor, Inc. (XNCR) Stock Analysis: Exploring a 95.60% Potential Upside in the Biotech Sector

Xencor, Inc. (NASDAQ: XNCR), a dynamic player in the biotechnology industry, is garnering significant attention from investors due to its innovative approach in developing engineered monoclonal antibodies. Headquartered in Pasadena,..

Collegium Pharmaceutical, Inc. (COLL) Stock Report: A 34.3% Potential Upside with Strong Buy Ratings

Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a prominent player in the healthcare sector specializing in pain management medications, is currently capturing investor attention with its significant potential upside. With a market..

Vir Biotechnology, Inc. (VIR) Stock Analysis: A 185% Upside Amidst Biotech Challenges

Vir Biotechnology, Inc. (NASDAQ: VIR) has captured investor attention with its notable potential upside of 185.14%, making it a compelling consideration for those interested in the biotechnology sector. Despite the..

iRadimed Corporation (IRMD) Stock Analysis: Healthcare Innovator with Strong Revenue Growth and High RSI

iRadimed Corporation (NASDAQ: IRMD), a prominent player in the medical devices industry, is capturing investor attention with its innovative MRI-compatible medical products and robust financial performance. Headquartered in Winter Springs,..

Sionna Therapeutics, Inc. (SION): A 34% Upside Amid Biotech Innovations

Sionna Therapeutics, Inc. (SION), a dynamic player in the healthcare sector, is making significant strides in the biotechnology industry. With a focus on developing transformative treatments for cystic fibrosis (CF),..

Dianthus Therapeutics, Inc. (DNTH) Stock Report: A Strategic Look at Its 78% Potential Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a pioneering name in the biotechnology sector, is grabbing investor attention with its impressive 78.30% potential upside. This clinical-stage biotech company, headquartered in New York,..

CorMedix Inc. (CRMD) Stock Analysis: A Biotech Powerhouse with 86% Upside Potential

CorMedix Inc. (CRMD), a dynamic player in the biotechnology sector, is capturing investor attention with its promising financial metrics and significant upside potential. With a market capitalization of $858.65 million,..

Cogent Biosciences, Inc. (COGT): Analyst Ratings Point to a Promising 30% Upside

Investors eyeing the biotechnology sector may want to consider Cogent Biosciences, Inc. (NASDAQ: COGT), a company that has recently captured attention with its strong analyst ratings and substantial growth potential...

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Unveiling a 47.93% Potential Upside in Rare Disease Market

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is making waves in the healthcare sector with its strategic focus on rare diseases. As a specialty and generic drug manufacturer headquartered in Deer Park,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds